Eloxx Pharmaceuticals Inc (ELOX)

Industry Biotechnology


This stock can be held in an Investment ISA and an Investment Account
Sell

$

Buy

$

arrow-up$ (+%)

Prices updated at 13 Dec 2025, 23:37
| Prices minimum 15 mins delay
|
Prices in USD

Eloxx Pharmaceuticals Inc is a United States-based clinical-stage pharmaceutical company. It is focused on building and developing a portfolio of therapeutics for the treatment of cancer and immunological diseases.
Sector
Healthcare
Industry
Biotechnology
Chairman
Mr. Tomer Kariv
CEO
Mr. Sumit Aggarwal
Most recent earnings
31 Dec 2022
Fiscal year end
31 Dec 2022
Employees
18
Head office
P.O. Box 274
Arlington
United States
02476
mobile
+1 781 577-5300
letter
barbarar@eloxxpharma.com

Key personnel

Salary
Mr. Steven D. Rubin
Independent Director
0.06m
Mr. Tomer Kariv
Chairman of the Board
0.05m
Mr. Daniel E. Geffken, M.B.A.
Interim Chief Financial Officer and Principal Accounting Officer
-
Mr. Sumit Aggarwal
Director, President and Chief Executive Officer
0.58m
Dr. Alan Walts
Independent Director
0.06m
Ms. Lindsay Androski
Independent Director
0.03m

Top 5 shareholders

No. of shares
Northern Trust Investments Inc101
NT Quality SCC US Fund - L101
Northern Trust Asset Management-
BlackRock Asset Management Canada Ltd-
BlackRock Fund Advisors-

Director dealings

Action
16 Oct 2024-
16 Oct 2024-
16 Oct 2024-
16 Oct 2024-
24 Jan 2024-
24 Jan 2024-
24 Jan 2024-
24 Jan 2024-
24 Jan 2025-
24 Jan 2025-
24 Jan 2025-
24 Jan 2025-
24 Jan 2025-
24 Jan 2025-
24 Jan 2025-
24 Jan 2025-
Please note that past performance is not a reliable indicator of future returns.


Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2025 Morningstar. All rights reserved.